[go: up one dir, main page]

JPH04348757A - Dialysate treatment method and treatment device - Google Patents

Dialysate treatment method and treatment device

Info

Publication number
JPH04348757A
JPH04348757A JP2415264A JP41526490A JPH04348757A JP H04348757 A JPH04348757 A JP H04348757A JP 2415264 A JP2415264 A JP 2415264A JP 41526490 A JP41526490 A JP 41526490A JP H04348757 A JPH04348757 A JP H04348757A
Authority
JP
Japan
Prior art keywords
dialysate
dialyzate
adsorption layer
dialysis
outlet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2415264A
Other languages
Japanese (ja)
Inventor
Shingo Takezawa
竹沢 真吾
Hideo Hidai
日台 英雄
Kiyotaka Sakai
清孝 酒井
Takeshi Utsugi
宇都木 毅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHIYADAN ZENNINKAI
Ise Chemicals Corp
Original Assignee
SHIYADAN ZENNINKAI
Ise Kagaku Kogyo KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHIYADAN ZENNINKAI, Ise Kagaku Kogyo KK filed Critical SHIYADAN ZENNINKAI
Priority to JP2415264A priority Critical patent/JPH04348757A/en
Publication of JPH04348757A publication Critical patent/JPH04348757A/en
Pending legal-status Critical Current

Links

Landscapes

  • Loading And Unloading Of Fuel Tanks Or Ships (AREA)
  • External Artificial Organs (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)

Abstract

PURPOSE:To obtain the method and device for treating a dialyzate which allow easy handling and decrease pressure drops by passing the dialyzate through the inside of an adsorption layer consisting of many porous materials having many pores to adsorb and remove the low mol. wt. protein contained in the dialyzate. CONSTITUTION:A pipe 8 is liquicltightly connected to an outlet 3 side of the device for treating the dialyzate and is connected to a dialysis device 9. The dialysis device 9 has many dialyzing tubes 10 consisting of semipermeable membranes, an outside pipe 11, a blood supply pipe 12, a blood discharge pipe 13, and a dialyzate outlet 14. Blood flows in the inside of the dialyzing tubes 10 and the dialyzate flows on the outside of the dialyzing tubes 10, respectively like arrows. The dialysis is executed through the semipermeable membranes constituting the dialyzing tubes 10. The harmful components in the dialyzate migrate into the dialyzate during this time and the dialyzate contg. the harmful components is discarded by a pump, etc., from an outlet 14. The adsorption layer is adequately packed with the powdery porous materials, such as porous glass powder and active carbon.

Description

【発明の詳細な説明】[Detailed description of the invention]

【0001】0001

【産業上の利用分野】本発明は、血液を透析処理するた
めに用いる透析液の処理方法並びに処理装置に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a method and apparatus for treating dialysate used for dialysis of blood.

【0002】0002

【従来の技術】透析液中に混入している菌体、発熱物質
等を除菌フィルター、ポリアミド膜等を用いて除去する
ことは知られている。
BACKGROUND OF THE INVENTION It is known to remove bacteria, pyrogens, etc. contained in a dialysate using a sterilizing filter, a polyamide membrane, or the like.

【0003】0003

【発明が解決しようとする課題】透析膜の改良により、
従来は不可能と思われていたβ2−マイクログロブリン
(以下β2−MGと略称)のような低分子タンパク質ま
でも拡散で除去できるようになった。膜によっては通常
の透析においてβ2−MGのクリアランスが40ml/
min近くにも達するものがある。一方、膜そのものへ
タンパク質を吸着させて除去するタイプもあり、低分子
タンパク質の除去能は臨床での要求に答えるべくますま
す向上すると思われる。しかし、拡散による除去の場合
、血液側から透析液側へ除去できると同時に、透析液側
の同程度の分子量を有するタンパク質等も濃度差があれ
ば血液側へ侵入する。その侵入の程度は限外濾過を多く
してもさほど低下せず、通常の透析条件下では防ぐこと
ができない。これら透析液中の低分子タンパク質等の一
部は生体にとって充分毒性や抗原性があるとみなせ、透
析中の発熱など諸症状をきたすばかりでなく、長期にわ
たる場合は免疫系の異常につながる恐れもある。そのた
め、高透過性膜を有するダイアライザーを用いるには、
透析液中の抗原性物質等をできる限り除去しなければな
らない。
[Problem to be solved by the invention] By improving the dialysis membrane,
Even low molecular weight proteins such as β2-microglobulin (hereinafter abbreviated as β2-MG), which was thought to be impossible in the past, can now be removed by diffusion. Depending on the membrane, the clearance of β2-MG in normal dialysis is 40ml/
Some reach close to min. On the other hand, there is also a type that removes proteins by adsorbing them to the membrane itself, and it is expected that the ability to remove low-molecular-weight proteins will continue to improve to meet clinical demands. However, in the case of removal by diffusion, it is possible to remove from the blood side to the dialysate side, and at the same time, proteins having similar molecular weights on the dialysate side also enter the blood side if there is a difference in concentration. The extent of its invasion is not significantly reduced by increased ultrafiltration and cannot be prevented under normal dialysis conditions. Some of these low-molecular-weight proteins in the dialysate are considered to be sufficiently toxic and antigenic to living organisms, and not only can they cause various symptoms such as fever during dialysis, but if continued over a long period of time, they may lead to abnormalities in the immune system. be. Therefore, in order to use a dialyzer with a highly permeable membrane,
Antigenic substances, etc. in the dialysate must be removed as much as possible.

【0004】透析液中から菌体を除去するには透析液ラ
インの頻繁な洗浄を行い、除菌フィルターを取り付けれ
ばよいが、菌体をダイアライザー直前でトラップしても
それから出てきうる低分子タンパク質等までもトラップ
することはできない。カットオフポイントが20,00
0程度のポリアミド膜を用いてダイアライザー直前で菌
体と一緒に発熱物質までをも除去する方法もあるが、膜
面積が2m2必要であり、洗浄やコストを考えると普及
は難しいと思われる。
Bacterial cells can be removed from the dialysate by frequently cleaning the dialysate line and installing a sterilization filter, but even if the bacterium is trapped just before the dialyzer, low-molecular proteins that may come out from it may be removed. etc. cannot be trapped. Cutoff point is 20,00
There is also a method of removing pyrogens along with bacterial cells immediately before the dialyzer by using a polyamide membrane of about 0.0 mm, but this method requires a membrane area of 2 m2, and it is thought that it will be difficult to popularize it due to cleaning and cost considerations.

【0005】本発明は、上述した従来技術の有する問題
点を解消し、取り扱いも容易で圧力損失も少なく、透析
液中に含まれる低分子量のタンパク質等を有効に除去す
るための透析液の処理方法、並びに処理装置を提供する
ことを目的とする。
The present invention solves the above-mentioned problems of the prior art, is easy to handle, has little pressure loss, and provides treatment for dialysate to effectively remove low-molecular-weight proteins and the like contained in the dialysate. An object of the present invention is to provide a method and a processing apparatus.

【0006】[0006]

【課題を解決するための手段】本発明者は、透析液流量
、圧力損失、取り扱いやすさなどの種々の条件を考える
と、それらを除去するにはダイアライザー直前で吸着す
ることが最適と考え、かかる観点に立脚して、検討を行
い、本発明を完成した。そして、吸着剤として多孔質ガ
ラス、合成高分子、セルローズ、活性炭に着目し、いく
つかのタンパク質について吸着の度合を調べた。
[Means for Solving the Problem] Considering various conditions such as dialysate flow rate, pressure loss, and ease of handling, the present inventor believes that adsorption immediately before the dialyzer is the best way to remove them. Based on this viewpoint, we conducted studies and completed the present invention. They then focused on porous glass, synthetic polymers, cellulose, and activated carbon as adsorbents, and investigated the degree of adsorption of several proteins.

【0007】本発明は、上述した研究結果に基づく新た
なる提案であり、血液を透析処理するために用いる透析
液を、多数の細孔を有する多孔質物質よりなる吸着層中
を通過させ、透析液中に含まれる低分子量タンパク質を
吸着層中に吸着、除去することを特徴とする透析液の処
理方法並びに透析液の送給孔と、多数の小孔を有する多
孔質物質よりなる吸着層と透析液の排出孔とを有する透
析液の処理装置に関するものである。本発明処理装置の
好ましい態様においては、多孔質吸着物質として多孔質
ガラス、合成高分子、セルローズ又は活性炭を使用する
The present invention is a new proposal based on the above-mentioned research results, in which a dialysate used for dialysis treatment of blood is passed through an adsorption layer made of a porous material having a large number of pores. A dialysate treatment method characterized by adsorbing and removing low molecular weight proteins contained in the solution in an adsorption layer, and an adsorption layer comprising a dialysate feed hole and a porous material having a large number of small pores. The present invention relates to a dialysate treatment device having a dialysate discharge hole. In a preferred embodiment of the treatment apparatus of the present invention, porous glass, synthetic polymers, cellulose or activated carbon is used as the porous adsorbent.

【0008】本発明者は、本発明の方法並びに装置を具
体化するための諸元を求めるため、先づビーカーによる
バッチテストを行った。このバッチテストにおいて、伊
勢化学工業株式会社製の多孔質ガラス(商品名MPG)
微粉末(粒径100〜200μm)を使用し、又タンパ
ク質として表1記載のものを使用した。
[0008] The present inventor first conducted a batch test using a beaker in order to obtain specifications for embodying the method and apparatus of the present invention. In this batch test, porous glass (trade name MPG) manufactured by Ise Chemical Industry Co., Ltd.
Fine powder (particle size 100 to 200 μm) was used, and the proteins listed in Table 1 were used as proteins.

【表1】 次に、バッチテストの具体的方法並びにその結果に就い
て説明する。実験は、まずビーカー内にこれらタンパク
質溶液を各々入れ、その濃度の経時変化を調べた。溶媒
には酢酸透析液を用い、各タンパク質の初期濃度は1〜
10mg/dl とした。多孔質ガラス微粉末の量は1
g、溶液量は100mlとした。いずれの濃度も同一の
酢酸透析液をベースとした高感度直接比色法により分析
した。
[Table 1] Next, the specific method of the batch test and its results will be explained. In the experiment, each of these protein solutions was first placed in a beaker, and changes in their concentrations over time were investigated. Acetic acid dialysate was used as the solvent, and the initial concentration of each protein was 1 to 1.
It was set to 10 mg/dl. The amount of porous glass fine powder is 1
g, and the solution volume was 100 ml. Both concentrations were analyzed by a highly sensitive direct colorimetric method based on the same acetic acid dialysate.

【0009】図1にビーカーバッチによる吸着実験結果
を示す。濃度は経時的に減少しており、約60分後には
遊離濃度と吸着量が平衡に達する。この平衡状態の関係
をまとめると、図2のようになる。リゾチームが最もよ
く吸着され、チトクロムC、リボヌクレアーゼA、α−
ラクトアルブミンの順に吸着されていることがわかる。 この吸着傾向は等電点と同一であり、低分子タンパク質
の吸着能は電荷の影響を強く受けることがわかった。
FIG. 1 shows the results of an adsorption experiment using a beaker batch. The concentration decreases over time, and the free concentration and adsorption amount reach equilibrium after about 60 minutes. The relationship of this equilibrium state can be summarized as shown in FIG. 2. Lysozyme is the most commonly adsorbed, followed by cytochrome C, ribonuclease A, and α-
It can be seen that lactalbumin is adsorbed in this order. This adsorption tendency is the same as the isoelectric point, and it was found that the adsorption ability of low-molecular proteins is strongly influenced by charge.

【0010】この図より、式1で示されるフロイントリ
ッヒの吸着等温式の係数を求めると、リゾチームの場合
はkが0.012、nが11であった。これらパラメー
タはそのタンパク質が吸着されやすいかどうかの目安で
ある。α−ラクトアルブミンではkが0.001、nが
4である。プロットが少ないものの、これらをグラフ化
すると図3、図4のように右上がりの傾向となり、多孔
質ガラス微粉末には明らかに高等電点側のタンパク質が
吸着されやすいことが判明した。
[0010] From this figure, the coefficients of Freundlich's adsorption isotherm expressed by Equation 1 were determined, and in the case of lysozyme, k was 0.012 and n was 11. These parameters are indicators of whether the protein is likely to be adsorbed. For α-lactalbumin, k is 0.001 and n is 4. Although there are only a few plots, when these are graphed, they show an upward trend to the right as shown in FIGS. 3 and 4, and it is clear that proteins on the higher electric point side are easily adsorbed to the porous glass fine powder.

【数1】[Math 1]

【0011】次に、本発明の方法並びに装置を図5,図
6に基いて、更に具体的に説明する。本発明において多
数の小孔を有する多孔質物質としては、多孔質ガラス、
合成高分子、セルローズ、活性炭、特に多孔質ガラスが
好ましい。又多孔質ガラスとしてはバイコールガラス、
或はSiO245〜70wt%、B2O38〜30wt
%、CaO 8〜25wt%、Al2O3 5〜15w
t%、 Na2O 3〜8%、K2O 1〜5wt%、
 Na2O +K2O 4〜13wt%、MgO 0〜
8wt%なる組成を有するガラス(以下ガラスAという
)又はSiO245〜70wt%、B2O38〜30w
t%、CaO 8〜25wt%、Al2O3 5〜15
%なる組成を有するガラス(以下ガラスBという)を熱
処理してB2O3、CaO を主体とする相を分相せし
め、この相を溶解除去することによって得られる多孔質
ガラス(以下、多孔質ガラスA又Bと呼ぶ)が適当であ
る。
Next, the method and apparatus of the present invention will be explained in more detail with reference to FIGS. 5 and 6. In the present invention, porous materials having a large number of small pores include porous glass,
Synthetic polymers, cellulose, activated carbon, and especially porous glass are preferred. In addition, as porous glass, Vycor glass,
Or SiO245-70wt%, B2O38-30wt%
%, CaO 8-25wt%, Al2O3 5-15w
t%, Na2O 3-8%, K2O 1-5wt%,
Na2O + K2O 4~13wt%, MgO 0~
Glass having a composition of 8wt% (hereinafter referred to as glass A) or SiO245-70wt%, B2O38-30w
t%, CaO 8-25wt%, Al2O3 5-15
A porous glass (hereinafter referred to as porous glass A or ) is appropriate.

【0012】又、合成高分子としてはポリスルフォン等
が、セルローズとしてはイオン交換型セルロース等を用
いるのが好ましい。活性炭としては粒度8〜200メッ
シュ望ましくは16〜32メッシュのものが好ましい。 図5,図6において、1は透析液の処理装置(カラム)
で、透析液の入口2、透析液の出口3を有するパイプ4
中に充填された多孔質ガラス粒よりなる吸着層5及び多
数の小孔を有する目板6,6とを備えている。
[0012] Furthermore, it is preferable to use polysulfone or the like as the synthetic polymer, and ion-exchange cellulose or the like as the cellulose. The activated carbon preferably has a particle size of 8 to 200 mesh, preferably 16 to 32 mesh. In Figures 5 and 6, 1 is a dialysate processing device (column)
and a pipe 4 having a dialysate inlet 2 and a dialysate outlet 3
It includes an adsorption layer 5 filled with porous glass particles and batten plates 6, 6 having a large number of small holes.

【0013】透析液の処理装置の入口2側にはパイプ7
が気密に接続され、パイプ7は透析液の供給装置(図示
せず)に接続され、入口から所定流量の透析液が供給さ
れ、吸着層5で透析液中に含まれる低分子量タンパク質
等が吸着除去される。
A pipe 7 is provided on the inlet 2 side of the dialysate treatment device.
are airtightly connected, the pipe 7 is connected to a dialysate supply device (not shown), a predetermined flow rate of dialysate is supplied from the inlet, and the adsorption layer 5 adsorbs low molecular weight proteins etc. contained in the dialysate. removed.

【0014】透析液の処理装置1の出口3側には、パイ
プ8が気密に接続され、パイプ8は透析装置9に接続さ
れている。透析装置9は半透膜よりなる多数の透析管1
0、外管11、血液の供給管12、血液の排出管13、
透析液の出口14を備え、血液は透析管10の内部を、
透析液は透析管10の外側を、夫々矢印のように流れ、
透析管10を構成する半透膜を通して血液の透析が行な
われる。この間に血液中の有害成分は透析液中に移行し
、この有害成分を含んだ透析液は出口14からポンプ等
(図示せず)により廃棄される。
A pipe 8 is airtightly connected to the outlet 3 side of the dialysate treatment device 1, and the pipe 8 is connected to a dialysis device 9. A dialysis device 9 includes a large number of dialysis tubes 1 made of semipermeable membranes.
0, outer tube 11, blood supply tube 12, blood discharge tube 13,
A dialysate outlet 14 is provided, and blood flows through the inside of the dialysis tube 10.
The dialysate flows on the outside of the dialysis tube 10 as shown by the arrows,
Blood is dialyzed through a semipermeable membrane that constitutes the dialysis tube 10. During this time, harmful components in the blood migrate into the dialysate, and the dialysate containing the harmful components is discarded from the outlet 14 by a pump or the like (not shown).

【0015】なお、吸着層は多孔質ガラスパウダー、活
性炭のような粉末状の多孔質物質を充填したものを好適
に用いることができるが、薄板状の多孔質ガラス板を用
いることもでき、更に又ブロック状もしくは、ファイバ
ー状の合成高分子またはセルロースを用いることもでき
る。
[0015] The adsorption layer may preferably be one filled with a porous material such as porous glass powder or activated carbon, but a thin porous glass plate may also be used. Furthermore, block-shaped or fibrous synthetic polymers or cellulose can also be used.

【0016】多孔質物質の細孔直径は、吸着、除去する
タンパク質の分子量等に応じて実験的に定めることがで
きる。
The pore diameter of the porous material can be determined experimentally depending on the molecular weight of the protein to be adsorbed or removed.

【0017】例えば分子量が12,000〜15,00
0の場合、平均細孔直径1,500Åの多孔質ガラスを
用いて好適な結果をうることができた。吸着層の厚みは
、吸着速度、透析液の流速に応じ、吸着層中の透析液の
滞留時間が所定値以上となるよう実験的に定める。
For example, if the molecular weight is 12,000 to 15,00
In the case of 0, suitable results could be obtained using porous glass with an average pore diameter of 1,500 Å. The thickness of the adsorption layer is experimentally determined depending on the adsorption rate and the flow rate of the dialysate so that the residence time of the dialysate in the adsorption layer is equal to or greater than a predetermined value.

【0018】吸着速度はタンパク質の拡散係数、すなわ
ちタンパク質分子の大きさと吸着するときの溶液温度に
よって左右されるが、吸着剤側の因子として、パウダー
周囲の流れ具合い、すなわち流れの均一化及び多孔質物
質近傍にできる境膜での移動具合いと、多孔質物質表面
や内部(細孔内)への拡散しやすさに大別される。多孔
質物質周囲の流れ具合いは多孔質物質の粒径、パイプ(
カラム)への充填状態、パイプ形状、透析液流量が影響
を与える。一方、多孔質物質そのものへの拡散状態は多
孔質物質の表面構造、細孔半径およびその分布により左
右される。接触面積を考えると、多孔質物質粒径は小さ
い方が有利である。しかし、圧力損失が大きくなるため
、極端な微細化はできない。
The adsorption rate is influenced by the diffusion coefficient of the protein, that is, the size of the protein molecule, and the solution temperature at the time of adsorption, but factors on the adsorbent side include the flow condition around the powder, that is, the uniformity of the flow and the porosity. It can be broadly divided into the degree of movement through a film formed near a substance, and the ease with which it diffuses to the surface and inside (inside pores) of a porous substance. The flow condition around a porous material depends on the particle size of the porous material and the pipe (
The packing condition of the column (column), pipe shape, and dialysate flow rate have an effect. On the other hand, the state of diffusion into the porous material itself depends on the surface structure of the porous material, the pore radius, and its distribution. Considering the contact area, it is advantageous that the particle size of the porous material is smaller. However, extreme miniaturization is not possible due to the increased pressure loss.

【0019】例えば、粒径100〜200μm、平均細
孔直径1,500Åのガラス粉末を充填した、充填層の
厚さ10mm、内径10mmの透析液の処理装置(カラ
ム)を用いた場合、透析液の滞留時間0.1〜11秒で
は除去率が変らず100%程度であった。
For example, when using a dialysate processing device (column) filled with glass powder having a particle size of 100 to 200 μm and an average pore diameter of 1,500 Å, a packed bed thickness of 10 mm, and an inner diameter of 10 mm, the dialysate When the residence time was 0.1 to 11 seconds, the removal rate remained unchanged at about 100%.

【0020】いま、仮りにダイアライザー直前に吸着カ
ラムを取り付けることを想定する。ダイアライザーの透
析液入口ポート部の内直径は9mmほどなので、透析液
流量500ml/minのときに滞留時間が0.1秒と
なるカラム長さを求めると3cm程度である。なお、こ
こで多孔質物質パウダーの充填密度を50%とした。理
想的にはダイアサイザー同様使い捨てにできるとよい。 充分な吸着がなされるかどうかは多孔質物質パウダー形
状の外に充填状態が大きく影響を与えると思われる。ま
た、5時間もしくはそれ以上にわたって流れる透析液を
処理できるかどうかは充填量に左右され、透析液中の除
去すべきタンパク質濃度等がおおよそ決まれば必要量は
おのずと決定され、カラムの形状を定めることができる
Now, let us assume that an adsorption column is installed immediately before the dialyzer. Since the inner diameter of the dialysate inlet port of the dialyzer is approximately 9 mm, the column length at which the residence time is 0.1 seconds when the dialysate flow rate is 500 ml/min is approximately 3 cm. Note that here, the packing density of the porous material powder was set to 50%. Ideally, it would be disposable like the diasizer. Whether or not sufficient adsorption is achieved is thought to be greatly influenced by the filling state in addition to the shape of the porous material powder. In addition, whether or not it is possible to process dialysate flowing for 5 hours or more depends on the packing volume, and once the protein concentration to be removed in the dialysate is approximately determined, the required volume is automatically determined, and the shape of the column must be determined. Can be done.

【0021】上述したように、カラムを小型化するため
には、実験的に解決すべき問題点は残されているが、本
発明の方法装置を用いることにより透析液中の低分子タ
ンパク質等を効果的に除去できることが判明した。
As mentioned above, there are still problems to be solved experimentally in order to miniaturize the column, but by using the method and apparatus of the present invention, it is possible to reduce low molecular weight proteins, etc. in the dialysate. It has been found that it can be effectively removed.

【0022】[0022]

【作用】血液を透析処理するために用いる透析液を、多
数の小孔を有する多孔質物質よりなる吸着層中を通過さ
せ、透析液中に含まれる低分子量タンパク質等を吸着層
に吸着、除去することにより、透析液中の菌体、発熱物
質の増加を有効に防止する。
[Action] The dialysate used for dialysis of blood is passed through an adsorption layer made of a porous material with many small pores, and low molecular weight proteins, etc. contained in the dialysate are adsorbed and removed by the adsorption layer. By doing so, the increase in bacterial cells and pyrogens in the dialysate is effectively prevented.

【0023】[0023]

【実施例】内径10mmのガラス管内に、100〜20
0μmの大きさの、細孔直径1,500Åのガラス粉末
を1g充填してなる、吸着層の厚み10mmのカラムを
用いリゾチームを濃度1,000ng/mlの割合で含
む酢酸透析液を通過させ、流量を0.2〜0.55ml
/secの割合で変化させ、カラム中の平均滞留時間2
.7sec 、5.6sec 、10.8sec にお
ける除去率及び除去率の経時変化を求めた。ここで除去
率は、
[Example] In a glass tube with an inner diameter of 10 mm, 100 to 20
An acetic acid dialysate containing lysozyme at a concentration of 1,000 ng/ml was passed through a column with an adsorption layer thickness of 10 mm and filled with 1 g of glass powder with a size of 0 μm and a pore diameter of 1,500 Å. Flow rate 0.2-0.55ml
/sec, the average residence time in the column 2
.. The removal rate at 7 sec, 5.6 sec, and 10.8 sec and the change in the removal rate over time were determined. Here, the removal rate is

【数2】 により計算した。平均滞留時間0.1から10sec 
で除去率に差がみられず、平均滞留時間0.1sec 
でも、除去率はほぼ100%で有効にリゾチームを除去
できることが判明した。
Calculated by [Equation 2]. Average residence time 0.1 to 10 seconds
There was no difference in the removal rate, and the average residence time was 0.1 sec.
However, it was found that lysozyme can be effectively removed with a removal rate of almost 100%.

【0024】又この操作を30分間継続した場合のでも
除去率の低下傾向は認められなかった。なお、プロット
がややバラついているのは出口濃度が低いための誤差で
ある。滞留時間がこの範囲内のとき除去率が一定とみな
せるということは、多孔質物質へのタンパク質吸着がき
わめて速やかに行われ、0.1秒以内にカラム出口で濃
度平衡に達していると理解することができる。なお、こ
の結果はビーカーバッチの結果と大きく異なるような感
じを受けるが、これはビーカーバッチではタンパク質濃
度が経時的に変化すること、多孔質物質パウダーと溶液
の接触状態が異なることが原因であり、低濃度タンパク
質の吸着が0.1秒以内で平衡に達することと矛盾しな
い。
Further, even when this operation was continued for 30 minutes, no tendency for the removal rate to decrease was observed. It should be noted that the slight variation in the plot is due to an error due to the low outlet concentration. The fact that the removal rate can be considered constant when the residence time is within this range means that protein adsorption to the porous material occurs extremely quickly, reaching concentration equilibrium at the column outlet within 0.1 seconds. be able to. Note that this result seems to be very different from the beaker batch result, but this is because the protein concentration changes over time in the beaker batch, and the contact conditions between the porous substance powder and the solution are different. , consistent with the adsorption of low-concentration proteins reaching equilibrium within 0.1 seconds.

【0025】[0025]

【実施例2】実施例1のガラス粉末に代え、活性炭の微
粉末(平均粒径80μm)を用いて同様な実験を行なっ
てほぼ同様の結果を得た。
Example 2 A similar experiment was conducted using fine activated carbon powder (average particle size 80 μm) in place of the glass powder of Example 1, and almost the same results were obtained.

【0026】[0026]

【発明の効果】短時間で、透析液中の低分子量タンパク
質等を効率的に除去できる。
[Effects of the Invention] Low molecular weight proteins and the like in the dialysate can be efficiently removed in a short time.

【0027】[0027]

【図面の簡単な説明】[Brief explanation of drawings]

【図1】ビーカーテストによる接触時間と濃度の関係を
示すグラフである。
FIG. 1 is a graph showing the relationship between contact time and concentration according to a beaker test.

【図2】平衡時における濃度と吸着量の関係を示すグラ
フである。
FIG. 2 is a graph showing the relationship between concentration and adsorption amount at equilibrium.

【図3】等電点と係数Kとの関係を示すグラフである。FIG. 3 is a graph showing the relationship between isoelectric point and coefficient K.

【図4】等電点と係数nとの関係を示すグラフである。FIG. 4 is a graph showing the relationship between isoelectric point and coefficient n.

【図5】本発明の装置の断面図である。FIG. 5 is a sectional view of the device of the invention.

【図6】図5の拡大断面図である。FIG. 6 is an enlarged sectional view of FIG. 5;

【符号の説明】[Explanation of symbols]

1    透析液の処理装置 2    透析液の入口 3    透析液の出口 4    パイプ 5    吸着層 9    透析装置 1 Dialysate processing equipment 2 Dialysate inlet 3 Dialysate outlet 4 Pipe 5 Adsorption layer 9 Dialysis machine

Claims (3)

【特許請求の範囲】[Claims] 【請求項1】  血液を透析処理するために用いる透析
液を、多数の細孔を有する多孔質物質よりなる吸着層中
を通過させ、透析液中に含まれる低分子量タンパク質を
吸着層に吸着、除去することを特徴とする透析液の処理
方法
Claim 1: A dialysate used for dialysis treatment of blood is passed through an adsorption layer made of a porous material having a large number of pores, and low molecular weight proteins contained in the dialysate are adsorbed to the adsorption layer. A method for treating dialysate characterized by removing
【請求項2】  透析液の送給孔と、多数の小孔を有す
る多孔質物質よりなる吸着層と、透析液の排出孔とを有
する透析液の処理装置
2. A dialysate treatment device comprising a dialysate feed hole, an adsorption layer made of a porous material having a large number of small holes, and a dialysate discharge hole.
【請求項3】  多孔物質は多孔質ガラス、合成高分子
、セルローズ又は活性炭である請求項2記載の処理装置
3. The processing apparatus according to claim 2, wherein the porous material is porous glass, synthetic polymer, cellulose, or activated carbon.
JP2415264A 1990-12-27 1990-12-27 Dialysate treatment method and treatment device Pending JPH04348757A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2415264A JPH04348757A (en) 1990-12-27 1990-12-27 Dialysate treatment method and treatment device

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2415264A JPH04348757A (en) 1990-12-27 1990-12-27 Dialysate treatment method and treatment device

Publications (1)

Publication Number Publication Date
JPH04348757A true JPH04348757A (en) 1992-12-03

Family

ID=18523642

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2415264A Pending JPH04348757A (en) 1990-12-27 1990-12-27 Dialysate treatment method and treatment device

Country Status (1)

Country Link
JP (1) JPH04348757A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241272B2 (en) 2001-11-13 2007-07-10 Baxter International Inc. Method and composition for removing uremic toxins in dialysis processes
JP2010279461A (en) * 2009-06-03 2010-12-16 Daicen Membrane Systems Ltd Method for cleaning artificial dialysis fluid or artificial dialysis water
US9764074B1 (en) 2002-07-19 2017-09-19 Baxter International Inc. Systems and methods for performing dialysis
US10646634B2 (en) 2008-07-09 2020-05-12 Baxter International Inc. Dialysis system and disposable set

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10980931B2 (en) 2001-11-13 2021-04-20 Baxter International Inc. System, method, and composition for removing uremic toxins in dialysis processes
US7241272B2 (en) 2001-11-13 2007-07-10 Baxter International Inc. Method and composition for removing uremic toxins in dialysis processes
US7955290B2 (en) 2001-11-13 2011-06-07 Baxter International Inc. Method and composition for removing uremic toxins in dialysis processes
US8002726B2 (en) 2001-11-13 2011-08-23 Baxter International Inc. Method and composition for removing uremic toxins in dialysis processes
US8066658B2 (en) 2001-11-13 2011-11-29 Baxter International Inc. Method and composition for removing uremic toxins in dialysis processes
US11235094B2 (en) 2002-07-19 2022-02-01 Baxter International Inc. System for peritoneal dialysis
US9764074B1 (en) 2002-07-19 2017-09-19 Baxter International Inc. Systems and methods for performing dialysis
US9814820B2 (en) 2002-07-19 2017-11-14 Baxter International Inc. Weight-controlled sorbent system for hemodialysis
US10179200B2 (en) 2002-07-19 2019-01-15 Baxter International Inc. Disposable cassette and system for dialysis
US10646634B2 (en) 2008-07-09 2020-05-12 Baxter International Inc. Dialysis system and disposable set
US11918721B2 (en) 2008-07-09 2024-03-05 Baxter International Inc. Dialysis system having adaptive prescription management
US11311658B2 (en) 2008-07-09 2022-04-26 Baxter International Inc. Dialysis system having adaptive prescription generation
US12472295B2 (en) 2008-07-09 2025-11-18 Baxter International Inc. Dialysis system having adaptive prescription management
JP2010279461A (en) * 2009-06-03 2010-12-16 Daicen Membrane Systems Ltd Method for cleaning artificial dialysis fluid or artificial dialysis water

Similar Documents

Publication Publication Date Title
JP3956363B2 (en) Cartridge useful for washing dialysate
US4612122A (en) Removing heavy metal ions from blood
EP2735360B1 (en) Adsorber device combining beads and hollow fiber membranes
JPH0829316B2 (en) How to remove Pyrogen
CA2644732C (en) Regeneratable filter for extracorporal treatment of liquids containing particles and use thereof
JP2004525747A5 (en)
EP0086028B1 (en) Water purifying method and system
JP2013518687A5 (en)
US10112000B2 (en) Method for reducing amyloid beta concentration in blood
EP2361645B1 (en) Use of a carrier for removal amyloid beta protein from extracorporeal fluids
US4741832A (en) Purification apparatus and method employing a regenerable ligand
JPH04348757A (en) Dialysate treatment method and treatment device
JPH0510104B2 (en)
JP2017525489A (en) Inflammatory mediators and systems for removing granulocytes and monocytes from blood
AU2021393431B2 (en) Dialysate filter
JPH04348756A (en) Method and device for treating dialyzate
Karoor et al. Immunoaffinity removal of xenoreactive antibodies using modified dialysis or microfiltration membranes
JPH1057476A (en) Membrane separator
JPH0611324B2 (en) Porous hollow fiber membrane
EP0673672A2 (en) Apparatus for processing liquids
JPS6125566A (en) porous membrane
JPS5827685A (en) Sterilized water-making unit
JPH11207150A (en) Liquid purifier using live bacterial and liquid purifying device
JP2004321720A (en) Production method of hollow fiber membrane type module and hollow fiber membrane type module
JPH0323177B2 (en)